In 1988, the first in-human TIL therapy was performed for the treatment of patients with metastatic melanoma; lymphocytes were extracted from resected melanoma, and after in vitro expansion, they were infused back into the melanoma patients, followed by interleukin 2 (IL-2) as an adjuvant therapy and cyclophosphamide as chemotherapy [86,87]. Here, IL2 is linked to metastatic melanoma.